NLS

The board of directors of Cantargia has announced the outcome of the rights issue of shares that was announced on 28 May 2026.

Veeva Systems has acquired Copli, focusing on agentic medical, legal, and regulatory (MLR) solutions for the life sciences industry.

Merck and Bio-Techne Corporation have entered into a definitive agreement pursuant to which Merck will, subject to customary closing conditions, acquire Bio-Techne for USD 73 per share in cash, representing a total enterprise value of approximately USD 11.3 billion, a 36% premium to Bio-Techne’s one-month volume weighted average trading price.

The agreement, building on a letter of intent announced earlier this year, is intended to establish a long-term partnership in spray-dried formulations, a technology considered important for the development of inhalable drug formulations for biologics, vaccines, and other large molecules.

Following the outcome of the DIAGNODE-3 study, the company’s immediate priority is to complete the close-out of the Phase 3 program in an efficient and responsible manner, it states.

The partnership will leverage Combotope’s SMART-Phage platform to generate highly tumor-selective antibodies for next-generation cancer therapies.